NeuroConnection.net

Earn 6 Hours of AMA PRA Category 1 Credit™

Time to Complete Activity:

1.0 hour per segment

Target Audience

This activity is intended for neurologists and other medical professionals with a specific interest in the management of Parkinson's Disease.

Learning Objectives:

At the conclusion of this continuing medical education activity, participants should be able to:

Diagnosis of Parkinson's Disease: Part 1 of 6

• Define the clinical features of Parkinson's Disease
• Identify the features that best predict Parkinson's Disease pathology
• Explain the role of screening in the diagnosis of Parkinson's Disease
• Understand the role of imaging in the diagnosis of Parkinson's Disease

Pharmacology Levodopa and Motor Complications: Part 2 of 6

• Identify the motor complications associated with levodopa treatment
• Explain the various treatment options available for preventing motor complications
• Define the options for treating motor complications

Pharmacology: Other Agents: Part 3 of 6

• Differentiate the various treatment options available for initial treatment of Parkinson's Disease
• Identify the mechanisms of action of the medications available for the symptomatic treatment of both early and advanced Parkinson's Disease
• Discuss the pros and cons of levodopa
• Discuss the pros and cons of the ancillary treatment options for Parkinson's Disease

Neuroprotection: Scientific Concepts: Part 4 of 6

• Define neuroprotection
• Describe the need for neuroprotection
• Explain the obstacles to determining neuroprotection
• Discuss the mechanisms of action of available agents that could potentially confer neuroprotection

Neuroprotection: Attempts to Date: Part 5 of 6

• Discuss the limitations of current study designs to assess neuroprotection
• Explain the Delayed Start design
• Identify candidate agents for neuroprotection
• Explain the positive and negative outcomes of neuroprotection clinical trials

The ADAGIO Study and Future Directions: Part 6 of 6

• Describe the ADAGIO Study and its endpoints
• Describe the results of the ADAGIO study
• Identify future directions in defining neuroprotective treatments

Designation Statement

Ciné-Med, Inc. designates this educational activity for a maximum of 6.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

How to get CME credit

To receive credit, participants must view the webcast or DVD, register on this site, and successfully complete the post-test and evaluation (successful passing grade >70%). Certificates can be printed on line.

Accreditation

This educational activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Ciné-Med, Inc. and Peer Health Communications. Ciné-Med, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

Disclosure statement

Ciné-Med, In accordance with the ACCME's Standards for Commercial Support, requires individuals with control over content to disclose to learners any relevant financial relationships(s). Faculty disclosures can be found on the Faculty page.